Endocrinologia, Diabetes y Nutricion最新文献

{"title":"Hypoglycemia in older adults with type 2 diabetes mellitus: Prevalence and associated risk factor: A systematic review and meta-analysis","authors":"Yuelin Wang ,&nbsp;Yunlan Jiang ,&nbsp;Le Li ,&nbsp;Hong Chen ,&nbsp;Jing Wang ,&nbsp;Mengjie Zhang ,&nbsp;Xiaoyu Bai ,&nbsp;Senlin Wu","doi":"10.1016/j.endinu.2025.501759","DOIUrl":"10.1016/j.endinu.2025.501759","url":null,"abstract":"<div><h3>Background</h3><div>Currently, hypoglycemia poses a critical challenge in managing older patients with type 2 diabetes mellitus (T2DM), threatening their long-term health and overall well-being. This meta-analysis is the first to comprehensively quantify the pooled prevalence of hypoglycemia and identify its key influencing factors specifically in the elderly population.</div></div><div><h3>Methods</h3><div>We conducted a systematic study across 11 databases to identify relevant observational studies reporting the prevalence of hypoglycemia or its influencing factors. The search was limited from database inception all the way until July 9th, 2025, and updated November 13th, 2025. In addition, we conducted a meta-analysis of the overall prevalence of hypoglycemia and its influencing factors using Stata 17.0 and RevMan 5.4, respectively.</div></div><div><h3>Results</h3><div>Among the 37 studies included, the overall prevalence of hypoglycemia in elderly patients with T2DM was 21% (95%CI, 20–23%). The results of this meta-analysis showed that age, diabetes duration, insulin treatment, hypertension, malignant tumors, renal impairment, cognitive dysfunction, and glycosylated hemoglobin were the key determinants influencing the risk of hypoglycemia in the elderly T2DM population.</div></div><div><h3>Conclusion</h3><div>Early clinical risk assessment is essential for older adults with type 2 diabetes mellitus at high risk of hypoglycemic complications, along with the implementation of evidence-based diagnostic and therapeutic protocols for hypoglycemia management.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 5","pages":"Article 501759"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147756448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myostatin in the pituitary–muscle axis: Roles in health and disease","authors":"Pedro Iglesias","doi":"10.1016/j.endinu.2025.501757","DOIUrl":"10.1016/j.endinu.2025.501757","url":null,"abstract":"<div><div>Myostatin (GDF-8), a TGF-β family myokine, regulates skeletal muscle growth and systemic metabolism and influences pituitary development and hormone secretion. This review summarizes experimental, translational, and clinical data linking myostatin to pituitary biology, including recent mouse evidence identifying muscle-derived myostatin as an endocrine driver of FSH synthesis via activin-type II/TGFBR1 signaling, with human confirmation pending. We analyze how pituitary disorders – growth hormone deficiency, acromegaly, hypercortisolism, central thyroid disease, central hypogonadism, and hypopituitarism – modify myostatin signaling, contributing to sarcopenia, anabolic resistance, and metabolic dysfunction. Across these conditions, human evidence remains limited and confounded by assay heterogeneity and comorbidities, as circulating myostatin often fails to mirror intramuscular changes. We propose an evidence framework emphasizing standardized assays (mature vs latent forms), longitudinal clinical cohorts, and integration of hormonal and functional endpoints. Myostatin remains a promising yet unvalidated biomarker and therapeutic target in endocrine-related muscle disease.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501757"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalencia de desnutrición, sarcopenia y obesidad sarcopénica en pacientes con insuficiencia cardiaca","authors":"M. Carmen Dameto Pons,&nbsp;Elena González Arnáiz,&nbsp;María Antequera González,&nbsp;María Casado Rodríguez,&nbsp;Diana García Sastre,&nbsp;María García Duque,&nbsp;Javier Castañón Alonso,&nbsp;Diana Ariadel Cobo,&nbsp;María D. Ballesteros Pomar","doi":"10.1016/j.endinu.2025.501718","DOIUrl":"10.1016/j.endinu.2025.501718","url":null,"abstract":"<div><h3>Introduction</h3><div>Malnutrition, sarcopenia and sarcopenic obesity have a significant impact on patients with heart failure. Therefore, it is important to perform nutritional assessment in this group of patients. The aim of this study is to determine the prevalence of malnutrition, sarcopenia and sarcopenic obesity in patients with heart failure, assess their quality of life, and eventually reassess their nutritional status.</div></div><div><h3>Methodology</h3><div>We conducted an observational study of patients with heart failure randomly referred by thecCardiology department and examined from 2021 through 2022 in the Nutrition department and then re-evaluated in 2024. The diagnosis of malnutrition was established using the GLIM criteria; sarcopenia was diagnosed according to EWGSOP2, and sarcopenic obesity according to the ESPEN/EASO criteria.</div></div><div><h3>Results</h3><div>A total of 41 patients were evaluated between 2021 and 2022, of whom 23 were re-evaluated in 2024. A total of 82.6% were men (mean age, 64 yeras [SD, 10.6]). Initially the prevalence of malnutrition was 21.7%; sarcopenia, 8.7%; and sarcopenic obesity, 4.3%. Caloric and protein requirements were not reached in 63.2% and 47.4%, respectively. A total of 26.1% of patients had a low calf circumference (CC) value; 100% had low lower limb strength, 90.9% had low gait speed, and 50% had low stability. All patients (100%) had a good quality of life as assessed by the MLHFQ questionnaire. At reassessment, the prevalence of malnutrition was 21.7%; sarcopenia, 17.4%; and sarcopenic obesity, 8.7%. Caloric and protein requirements were not reached in 60.9% and 78.3%, respectively. Furthermore, 52.2% had low CC value, 100% had low lower limb strength, 91.3% had low speed and 43.5% had low stability. A total of 91.3% had a good quality of life as assessed by the MLHFQ questionnaire.</div></div><div><h3>Conclusions</h3><div>Approximately 20% of patients with heart failure exhibit malnutrition at initial assessment and during follow-up. A high percentage of patients do not achieve nutritional requirements, presenting deterioration in functional tests and worsening quality of life. It is therefore advisable to establish early and sustained nutritional screening and assessment strategies in these patients, establishing the appropriate nutritional medical treatment.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501718"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Entre el beneficio y el riesgo: el papel de los suplementos alimenticios en endocrinología","authors":"Cristina Tejera-Pérez","doi":"10.1016/j.endinu.2025.501711","DOIUrl":"10.1016/j.endinu.2025.501711","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501711"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychopathological aspects of EDs in adolescents with type 1 diabetes: Findings from the DEPS-R and clinical outcomes","authors":"Meliha Esra Bilici ,&nbsp;Hümeyra Altıntaş ,&nbsp;Elif Özsu ,&nbsp;Zeynep Şıklar ,&nbsp;Merih Berberoğlu ,&nbsp;Zehra Aycan","doi":"10.1016/j.endinu.2025.501719","DOIUrl":"10.1016/j.endinu.2025.501719","url":null,"abstract":"<div><h3>Objective</h3><div>Adolescence is marked by significant physiological and psychological changes that can lead to body image dissatisfaction and eating disorders (ED). Adolescents with type 1 diabetes mellitus (T1DM) may engage in restrictive dieting or insulin manipulation to control weight, risking severe complications. This study aims to identify adolescents with T1DM at risk for diabetes-specific eating behaviors using the Diabetes-Specific Eating Problems Scale-Revised (DEPS-R) and assess associated psychopathological factors, including diabulimia.</div></div><div><h3>Methods</h3><div>Adolescents (10–18 years) with T1DM who were under follow-up in our clinic within the past year were included. Patients were categorized into 3 metabolic control groups according to HbA1c levels: good (&lt;7%), moderate (7–9%), and poor (&gt;9%) based on the cumulative glycemic index that was calculated from the average HbA1c values over the past year. Eating behaviors were assessed using the DEPS-R scale, with scores<!--> <!-->≥<!--> <!-->20 indicating risk for ED. Individuals with high DEPS-R scores (at-risk group) were referred for psychiatric evaluation.</div></div><div><h3>Results</h3><div>A total of 11.2% our of 80 adolescents, were identified as at risk for EDs. The mean DEPS-R score of the at-risk group was significantly higher vs the other group (25.8<!--> <!-->±<!--> <!-->3.5 vs 10.0<!--> <!-->±<!--> <!-->4.6, <em>p</em> <!-->&lt;<!--> <!-->0.001). No significant differences were observed for age, gender, height SDS, and relative BMI. Although the at-risk group had a higher cumulative glycemic index and longer diabetes duration, there was no statistical significance (<em>p</em> <!-->=<!--> <!-->0.29, 0.28, respectively). Logistic regression analysis, adjusted for age, sex, diabetes duration, and comorbidities, did not identify statistically significant predictors of high DEPS-R scores. A weak positive correlation was found between high DEPS-R scores and basal-bolus insulin therapy (<em>r</em> <!-->=<!--> <!-->0.09, <em>p</em> <!-->=<!--> <!-->0.03). Psychopathology was observed in 55% of high-risk adolescents, with a higher prevalence in the poor metabolic control subgroup.</div></div><div><h3>Conclusion</h3><div>Although the DEPS-R scale is a valuable tool for identifying not only EDs but also early changes in eating behaviors in adolescents with T1DM, psychiatric evaluation is essential for confirming underlying psychopathology. Psychological factors play a key role in shaping eating behaviors, highlighting the need for integrated care combining diabetes management with psychological support.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501719"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioelectrical impedance analysis-derived phase angle predicts sarcopenia in older adults with type 2 diabetes mellitus","authors":"Tingying Xiao ,&nbsp;Shiyue Zou ,&nbsp;Chunming Yuan ,&nbsp;Lijuan Gou ,&nbsp;Ying Dai ,&nbsp;Fang Chen ,&nbsp;Jing Lai ,&nbsp;Lixi Yang","doi":"10.1016/j.endinu.2025.501717","DOIUrl":"10.1016/j.endinu.2025.501717","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Sarcopenia is prevalent among older patients with type 2 diabetes mellitus (T2DM). The phase angle (PhA), derived from bioelectrical impedance analysis (BIA), is a potential marker for sarcopenia. This study aimed to explore the relationship between PhA and sarcopenia in older patients with T2DM and determine the PhA threshold for predicting sarcopenia.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study with 263 older patients with T2DM hospitalized at a Chinese tertiary referral center. Participants were categorized into sarcopenia (T2DM-SP) and non-sarcopenia (T2DM-NSP) groups. Logistic regression analysis was used to evaluate the PhA as an independent predictor of sarcopenia after adjusting for confounding factors. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of PhA in sarcopenia.</div></div><div><h3>Results</h3><div>PhA was significantly lower in the T2DM-SP group vs the T2DM-NSP group (4.523<!--> <!-->±<!--> <!-->0.627° vs 4.995<!--> <!-->±<!--> <!-->0.711°; <em>p</em> <!-->&lt;<!--> <!-->0.001). Moreover, the PhA was significantly related to sarcopenia, even after adjusting for age, sex, body mass index (BMI), and other covariates, PhA remained independently associated with sarcopenia (OR, 0.112; <em>p</em> <!-->=<!--> <!-->0.001), low HGS (OR, 0.220; <em>p</em> <!-->=<!--> <!-->0.007), and low ASMI (OR, 0.083; <em>p</em> <!-->&lt;<!--> <!-->0.001). ROC curve analysis determined the optimal PhA cutoff values for diagnosing sarcopenia as 5.35° for men (AUC, 0.717; <em>p</em> <!-->&lt;<!--> <!-->0.001) and 4.55° for women (AUC, 0.745; <em>p</em> <!-->&lt;<!--> <!-->0.001).</div></div><div><h3>Conclusions</h3><div>The study identified a significant relationship between sarcopenia and PhA among older patients with T2DM, which may serve as a valuable marker for predicting sarcopenia in this population. Further prospective studies are required to confirm these findings and clarify the underlying mechanisms.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501717"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RECALSEEN 2024. La atención al paciente en las unidades de endocrinología y nutrición del Sistema Nacional de Salud","authors":"M. Julia Ocón Bretón ,&nbsp;Juan José Díez ,&nbsp;Gabriel Olveira Fuster ,&nbsp;Alberto Fernández Martínez ,&nbsp;Alba Galdón Sanz-Pastor ,&nbsp;Nuria Vilarrasa García ,&nbsp;Beatriz Lardies Sánchez ,&nbsp;Emma Anda Apiñaniz ,&nbsp;Francisco Pita Gutiérrez ,&nbsp;Manuel Gahete Ortiz ,&nbsp;Juan José López Gómez ,&nbsp;Rosa Casañ Fernández ,&nbsp;Miguel Ángel Rubio Herrera ,&nbsp;Náyade del Prado ,&nbsp;Javier Escalada San Martín ,&nbsp;Francisco Javier Elola Somoza ,&nbsp;Ignacio Bernabeu Morón","doi":"10.1016/j.endinu.2025.501729","DOIUrl":"10.1016/j.endinu.2025.501729","url":null,"abstract":"<div><h3>Objectives</h3><div>RECALSEEN analyses the structure, activity and results of the Endocrinology and Nutrition Services and Units (S-U_EyN) of the Spanish National Health System (SNHS). This article presents data collected from the 2024 survey, as well as activity and outcome indicators from the SNHS Minimum Basic Data Set (CMBD) for 2007-2022.</div></div><div><h3>Material and methods</h3><div>Descriptive cross-sectional study of S-U_EyN in general acute care hospitals of the SNHS. Data obtained through an ad hoc survey referring to data from 2023 and discharges from S-U_EyN recorded in the CMBD (2022) were used.</div></div><div><h3>Results</h3><div>A total of 116 responses were obtained from S-U_EyN of 160 general acute care hospitals in the SNHS (72%). Fifty-six per cent of the S-U_EyN respondents were services or clinical management units. The average number of endocrinologists per S-U_EyN department was 8.4 (5.4), with an estimated rate of 2.9 endocrinologists per 100,000 inhabitants. In 74% of hospitals there is a Clinical Nutrition Unit (dependent on the S-U_EyN in 93% of cases) and 39% of S-U_EyNs have a day hospital. The portfolio of services offered by S-U_EyN is closely related to the complexity of the hospital. There is a significant trend to decline in hospitalisations for endocrine and nutritional diseases. Notable differences were found in resources, activity and outcomes between hospitals and autonomous communities. In relation to quality management and the implementation of good practices, there was still considerable room for improvement. The trend to worsening of short- and long-term complication indicators for diabetes mellitus in the period 2016-2022 should be analysed.</div></div><div><h3>Conclusions</h3><div>RECALSEEN provides relevant information on S-U_EyN and the evolution of endocrinology and nutrition care in the SNHS.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501729"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of arterial stiffness and plasma FGF23 levels in patients with hypoparathyroidism","authors":"Irene Berges-Raso ,&nbsp;Ismael Capel ,&nbsp;Albert Cano ,&nbsp;Rocío Pareja ,&nbsp;Jaume Almirall ,&nbsp;Ruth Cano ,&nbsp;Assumpta Caixàs ,&nbsp;Mercedes Rigla","doi":"10.1016/j.endinu.2025.501724","DOIUrl":"10.1016/j.endinu.2025.501724","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with hypoparathyroidism are at a higher cardiovascular risk (CVR) due to mechanisms that are not yet well understood. In patients with renal failure, fibroblast growth factor 23 (FGF23) has been associated with an increased calcification and arterial stiffness (AS), leading to an increased CVR. In hypoparathyroidism—due to the situation of hyperphosphatemia—an increase in FGF23 is also probable. There is a paucity of research examining the relationship between FGF23 levels and AS in patients with hypoparathyroidism. The present study aims to assess AS, by measuring aortic pulse wave velocity (aPWV), and FGF23 levels in patients with hypoparathyroidism vs age and sex matched healthy controls.</div></div><div><h3>Material and methods</h3><div>We conducted a cross-sectional descriptive study, and collected demographical data of patients and treatment characteristics (calcium and vitamin D doses). Furthermore, we measured aPWV using the SphygmoCorXCEL® device and assessed FGF23 and all other parameters of calcium–phosphorus metabolism in a blood and 24<!--> <!-->h-urine samples.</div></div><div><h3>Results and discussion</h3><div>A total of 20 subjects with hypoparathyroidism (85% postoperative) and 16 healthy matched controls were included. The mean age was 58.6 years (SD, 12.2). The mean course of the disease was 16.31 years (3–44). Regarding the general characteristics, the most remarkable finding was that patients had an estimated glomerular filtration rate (eGFR) significantly lower than controls (72.5 [SD, 21.25] vs 95.3 [SD, 12.21]<!--> <!-->ml/min/1.73<!--> <!-->m²; <em>p</em> <!-->&lt;<!--> <!-->0.001). FGF23 levels were clearly elevated in subjects with hypoparathyroidism (255.2 [35.9–1487.4] vs 61.9 [27.8–134.8]<!--> <!-->RU/mL; <em>p</em> <!-->&lt;<!--> <!-->0.05). A trend toward higher AS was observed in subjects with hypoparathyroidism (aPWV 8.4 [5.2–17.3] vs 6.9 [5.1–10.8]<!--> <!-->m/s; <em>p</em> <!-->=<!--> <!-->0.08), as well as a positive correlation between aPWV and time of disease progression (<em>r</em> <!-->=<!--> <!-->0.679; <em>p</em> <!-->&lt;<!--> <!-->0.01). A negative correlation was observed in subjects with hypoparathyroidism between aPWV and eGFR (−0.519; <em>p</em> <!-->&lt;<!--> <!-->0.05). We found no significant correlation between aPWV and FGF23 or with phosphate levels or calcium supplements or calcitriol doses used in replacement treatment.</div></div><div><h3>Conclusions</h3><div>In subjects with hypoparathyroidism there is a marked increase in FGF23 levels and a trend toward a higher AS, which correlates with disease duration. However, these findings may be conditioned by an impaired renal function that this pathological process entails. A causal relationship could not be established between the elevated levels of FGF23 and AS.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501724"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D deficiency and depression in diabetes mellitus: A systematic review and meta-analysis","authors":"Miriam Hernández-López ,&nbsp;Mónica Grande-Alonso ,&nbsp;Soledad Aguado-Henche ,&nbsp;Rafael Ramírez-Carracedo ,&nbsp;Alba Sebastián-Martín ,&nbsp;Rafael Moreno-Gómez-Toledano","doi":"10.1016/j.endinu.2025.501743","DOIUrl":"10.1016/j.endinu.2025.501743","url":null,"abstract":"<div><div>Diabetes mellitus (DM) is a major global health concern with rising prevalence and significant comorbidities. Among modifiable risk factors, vitamin D (VD) deficiency has been increasingly associated with both the development of DM and the presence of depressive symptoms. Given the relevance of psychological health in diabetes management, exploring the interrelationship between VD, depression, and diabetes is of growing scientific interest. To investigate this triad, we conducted a systematic review of human cohort studies across PubMed and Web of Science, focusing on the relationship between VD status and depression in diabetic patients. Meta-analyses were performed with Review Manager (RevMan 5.3, Cochrane, London, United Kingdom) using the inverse variance method, and funnel plots assessed publication bias. Despite the limited and heterogeneous literature, pooled analyses revealed a significant inverse association between VD levels and depression in diabetes (OR, 0.90, 95%CI, 0.84–0.96). Future longitudinal and interventional studies are needed to clarify causal pathways, considering sex differences and body composition. Confirming this relationship could inform preventive strategies that improve the quality of life of diabetic patients through targeted nutritional and vitamin-based interventions.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501743"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HbA1c y hemoglobina «La Desirade» ¿son compatibles para monitorizar al paciente con diabetes? Aportación de un caso clínico","authors":"Alba Barreiro Lusquiños,&nbsp;Ramiro Antonio Torrado Carrión,&nbsp;Carmen Blanco Barros","doi":"10.1016/j.endinu.2025.501731","DOIUrl":"10.1016/j.endinu.2025.501731","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 4","pages":"Article 501731"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147631572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}